Compare FET & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FET | LTGO |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 953.8M | 924.9M |
| IPO Year | 2007 | 2026 |
| Metric | FET | LTGO |
|---|---|---|
| Price | $69.24 | $13.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $52.25 |
| AVG Volume (30 Days) | 138.6K | ★ 242.3K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $791,474,000.00 | N/A |
| Revenue This Year | $15.23 | N/A |
| Revenue Next Year | $7.08 | N/A |
| P/E Ratio | $30.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.77 | $10.24 |
| 52 Week High | $91.99 | $25.93 |
| Indicator | FET | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 41.33 |
| Support Level | $67.50 | $11.00 |
| Resistance Level | $85.27 | $15.95 |
| Average True Range (ATR) | 4.04 | 1.60 |
| MACD | -0.48 | 0.13 |
| Stochastic Oscillator | 11.82 | 48.34 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.